Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia

Steven M. Devine, Ron Hoffman, Amit K. Verma, Rajul Shah, Basil A. Bradlow, Wendy Stock, Vera Maynard, Ellen Jessop, David Peace, Marianne Huml, Deana Thomason, Yi Hsiang Chen, Koen Van Besien

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Standard myeloablative conditioning prior to allogeneic hematopoietic stem cell (HSC) transplantation has been associated with significant toxicity in patients older than 45 years of age with myelofibrosis with myeloid metaplasia (MMM). We sought to evaluate the efficacy of a reduced-intensity conditioning regimen for allogeneic HSC transplantation in this setting. A regimen consisting of fludarabine (30 mg/m2 intravenously daily for 5 days) and melphalan (70 mg/m2 intravenously daily for 2 days) followed by transplantation of filgrastim-mobilized peripheral blood cells from HLA-identical siblings was administered to 4 older patients (median age, 56 years; range, 48-58 years) with advanced MMM. All patients achieved prompt neutrophil and platelet engraftment and have experienced a significant regression of splenomegaly and bone marrow fibrosis. All now have normal bone marrow cellularity. With a median follow-up of 13 months (range, 11-19 months), all 4 patients are alive with stable full-donor hematopoietic chimerism. These results support the feasibility and effectiveness of reduced-intensity conditioning prior to allogeneic HSC transplantation for older patients with advanced MMM.

Original languageEnglish (US)
Pages (from-to)2255-2258
Number of pages4
JournalBlood
Volume99
Issue number6
DOIs
StatePublished - Mar 15 2002
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Cell Transplantation
Stem cells
Blood Cells
Blood
Cells
Hematopoietic Stem Cell Transplantation
Bone
Melphalan
Platelets
Toxicity
Therapeutics
Chimerism
Splenomegaly
Siblings
Neutrophils
Blood Platelets
Transplantation
Bone Marrow
Conditioning (Psychology)

ASJC Scopus subject areas

  • Hematology

Cite this

Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. / Devine, Steven M.; Hoffman, Ron; Verma, Amit K.; Shah, Rajul; Bradlow, Basil A.; Stock, Wendy; Maynard, Vera; Jessop, Ellen; Peace, David; Huml, Marianne; Thomason, Deana; Chen, Yi Hsiang; Van Besien, Koen.

In: Blood, Vol. 99, No. 6, 15.03.2002, p. 2255-2258.

Research output: Contribution to journalArticle

Devine, SM, Hoffman, R, Verma, AK, Shah, R, Bradlow, BA, Stock, W, Maynard, V, Jessop, E, Peace, D, Huml, M, Thomason, D, Chen, YH & Van Besien, K 2002, 'Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia', Blood, vol. 99, no. 6, pp. 2255-2258. https://doi.org/10.1182/blood.V99.6.2255
Devine, Steven M. ; Hoffman, Ron ; Verma, Amit K. ; Shah, Rajul ; Bradlow, Basil A. ; Stock, Wendy ; Maynard, Vera ; Jessop, Ellen ; Peace, David ; Huml, Marianne ; Thomason, Deana ; Chen, Yi Hsiang ; Van Besien, Koen. / Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. In: Blood. 2002 ; Vol. 99, No. 6. pp. 2255-2258.
@article{e902dfb300af43e4bc4a256bbfbacd13,
title = "Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia",
abstract = "Standard myeloablative conditioning prior to allogeneic hematopoietic stem cell (HSC) transplantation has been associated with significant toxicity in patients older than 45 years of age with myelofibrosis with myeloid metaplasia (MMM). We sought to evaluate the efficacy of a reduced-intensity conditioning regimen for allogeneic HSC transplantation in this setting. A regimen consisting of fludarabine (30 mg/m2 intravenously daily for 5 days) and melphalan (70 mg/m2 intravenously daily for 2 days) followed by transplantation of filgrastim-mobilized peripheral blood cells from HLA-identical siblings was administered to 4 older patients (median age, 56 years; range, 48-58 years) with advanced MMM. All patients achieved prompt neutrophil and platelet engraftment and have experienced a significant regression of splenomegaly and bone marrow fibrosis. All now have normal bone marrow cellularity. With a median follow-up of 13 months (range, 11-19 months), all 4 patients are alive with stable full-donor hematopoietic chimerism. These results support the feasibility and effectiveness of reduced-intensity conditioning prior to allogeneic HSC transplantation for older patients with advanced MMM.",
author = "Devine, {Steven M.} and Ron Hoffman and Verma, {Amit K.} and Rajul Shah and Bradlow, {Basil A.} and Wendy Stock and Vera Maynard and Ellen Jessop and David Peace and Marianne Huml and Deana Thomason and Chen, {Yi Hsiang} and {Van Besien}, Koen",
year = "2002",
month = "3",
day = "15",
doi = "10.1182/blood.V99.6.2255",
language = "English (US)",
volume = "99",
pages = "2255--2258",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "6",

}

TY - JOUR

T1 - Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia

AU - Devine, Steven M.

AU - Hoffman, Ron

AU - Verma, Amit K.

AU - Shah, Rajul

AU - Bradlow, Basil A.

AU - Stock, Wendy

AU - Maynard, Vera

AU - Jessop, Ellen

AU - Peace, David

AU - Huml, Marianne

AU - Thomason, Deana

AU - Chen, Yi Hsiang

AU - Van Besien, Koen

PY - 2002/3/15

Y1 - 2002/3/15

N2 - Standard myeloablative conditioning prior to allogeneic hematopoietic stem cell (HSC) transplantation has been associated with significant toxicity in patients older than 45 years of age with myelofibrosis with myeloid metaplasia (MMM). We sought to evaluate the efficacy of a reduced-intensity conditioning regimen for allogeneic HSC transplantation in this setting. A regimen consisting of fludarabine (30 mg/m2 intravenously daily for 5 days) and melphalan (70 mg/m2 intravenously daily for 2 days) followed by transplantation of filgrastim-mobilized peripheral blood cells from HLA-identical siblings was administered to 4 older patients (median age, 56 years; range, 48-58 years) with advanced MMM. All patients achieved prompt neutrophil and platelet engraftment and have experienced a significant regression of splenomegaly and bone marrow fibrosis. All now have normal bone marrow cellularity. With a median follow-up of 13 months (range, 11-19 months), all 4 patients are alive with stable full-donor hematopoietic chimerism. These results support the feasibility and effectiveness of reduced-intensity conditioning prior to allogeneic HSC transplantation for older patients with advanced MMM.

AB - Standard myeloablative conditioning prior to allogeneic hematopoietic stem cell (HSC) transplantation has been associated with significant toxicity in patients older than 45 years of age with myelofibrosis with myeloid metaplasia (MMM). We sought to evaluate the efficacy of a reduced-intensity conditioning regimen for allogeneic HSC transplantation in this setting. A regimen consisting of fludarabine (30 mg/m2 intravenously daily for 5 days) and melphalan (70 mg/m2 intravenously daily for 2 days) followed by transplantation of filgrastim-mobilized peripheral blood cells from HLA-identical siblings was administered to 4 older patients (median age, 56 years; range, 48-58 years) with advanced MMM. All patients achieved prompt neutrophil and platelet engraftment and have experienced a significant regression of splenomegaly and bone marrow fibrosis. All now have normal bone marrow cellularity. With a median follow-up of 13 months (range, 11-19 months), all 4 patients are alive with stable full-donor hematopoietic chimerism. These results support the feasibility and effectiveness of reduced-intensity conditioning prior to allogeneic HSC transplantation for older patients with advanced MMM.

UR - http://www.scopus.com/inward/record.url?scp=0037085757&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037085757&partnerID=8YFLogxK

U2 - 10.1182/blood.V99.6.2255

DO - 10.1182/blood.V99.6.2255

M3 - Article

C2 - 11877308

AN - SCOPUS:0037085757

VL - 99

SP - 2255

EP - 2258

JO - Blood

JF - Blood

SN - 0006-4971

IS - 6

ER -